Table 1. Clinicopathological characteristics of patients.
| Characteristics | n=159 |
|---|---|
| Age (years) | 57 [27–69] |
| Sex (male/female) | 114/45 |
| Etiology | |
| Viral hepatitis C | 96 |
| Viral hepatitis B | 43 |
| Viral hepatitis C/B | 5 |
| Others | 15 |
| AFP | 28.5 (1.3–12,727) |
| DCP | 42 [5–20,600] |
| Child Pugh (A/B/C) | 20/59/80 |
| MELD | 15.8 [4–41] |
| Maximum tumor size (cm) | 2 [0.4–3] |
| Classification | Well 23/mod 112/poor 24 |
| Number of tumors | 2 [1–186] |
| Preoperative treatment | 109 (69%) |
| HR | 1 |
| HR + TACE | 4 |
| HR + RFA | 3 |
| HR + TACE + RFA | 7 |
| TACE | 33 |
| RFA | 22 |
| TACE + RFA | 39 |
| Radiation | 0 |
| Chemotherapy | 0 |
| Milan criteria met | 124 (78%) |
| Kyoto criteria met | 132 (83%) |
AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; MELD, model for end-stage liver disease; HR, hepatic resection; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation.